AIM - To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
RESULTS - Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
CONCLUSIONS - The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.
Exp Oncol. 2015 Jun;37(2):154-5.
Plonis J1, Nakazawa-Miklasevica M1, Malevskis A2, Vaganovs P1, Pildava S3, Vjaters E1, Gardovskis J1, Miklasevics E1.
1 Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
2 Center of Urology, Pauls Stradins University Hospital, Riga LV-1007, Latvia.
3 Center for Disease Prevention and Control, Riga LV-1007, Latvia.